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Abstract
Introduction
We aimed to compare the effects of intraoperative lidocaine and magnesium on postopera-
tive functional recovery and chronic pain after mastectomy due to breast cancer. Systemic
lidocaine and magnesium reduce pain hypersensitivity to surgical stimuli; however, their
effects after mastectomy have not been evaluated clearly.
Methods
In this prospective, double-blind, clinical trial, 126 female patients undergoing mastectomy
were randomly assigned to lidocaine (L), magnesium (M), and control (C) groups. Lidocaine
and magnesium were administered at 2 mg/kg and 20 mg/kg for 15 minutes immediately
after induction, followed by infusions of 2 mg/kg/h and 20 mg/kg/h, respectively. The control
group received the same volume of saline. Patient characteristics, perioperative parame-
ters, and postoperative recovery profiles, including the Quality of Recovery 40 (QoR-40) sur-
vey, pain scales, length of hospital stay, and the short-form McGill pain questionnaire (SF-
MPQ) at postoperative 1 month and 3 months were evaluated.
Results
The global QoR-40 scores on postoperative day 1 were significantly higher in group L than
in group C (P = 0.003). Moreover, in sub-scores of the QoR-40 dimensions, emotional state
and pain scores were significantly higher in group L than those in groups M and C (P = 0.027
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and 0.023, respectively). At postoperative 3 months, SF-MPQ and SF-MPQ-sensitive
scores were significantly lower in group L than in group C (P = 0.046 and 0.036,
respectively).
Conclusions
Intraoperative infusion of lidocaine improved the quality of recovery and attenuated the
intensity of chronic pain in patients undergoing breast cancer surgery.
Introduction
At most, 60% of patients who undergo mastectomy for breast cancer experience chronic pain
[1,2], which could deteriorate a patient’s mood, activity, and social function [3,4]. Chronic
pain after breast cancer surgery is a significant problem that is expected to become more rele-
vant because the number of patients undergoing breast cancer surgery is increasing owing to
the longer survival associated with this surgery.
Many researchers have attempted to improve functional recovery after surgery, as well as
acute and chronic pain, with multimodal analgesic methods, including regional and/or systemic
analgesia consisting of opioid or other perioperative medications. Several studies have shown that
regional analgesia, such as paravertebral block and pectoral nerves block provide better functional
recovery or superior pain control after breast cancer surgery [5–7]. However, regional analgesia
for breast surgery is not widely used because of its innate risk (e.g., nerve injury or bleeding, espe-
cially in patients receiving anticoagulant therapy) and technical challenges. Therefore, easily
applicable, safe, and effective alternative analgesic methods are needed.
Recently, perioperative systemic lidocaine and magnesium have been reported to minimize
postoperative pain and reduce postoperative morphine consumption [8,9]. However, there has
been only one study [10] comparing the effects of systemic lidocaine and magnesium for improv-
ing postoperative outcomes, and it focused on relieving acute postoperative pain in patients
undergone laparoscopic cholecystectomy.
Therefore, we aimed to investigate the effects of intraoperative systemic lidocaine and
magnesium on postoperative functional recovery and chronic pain in patients undergoing
mastectomy.
Methods
This study was a single-center, prospective, double-blind, randomized clinical trial. The proto-
col was approved by the Institute Research Committee at Severance Hospital, Yonsei Univer-
sity Health System in Seoul, Republic of Korea, 2 July on 2014 (IRB number: 4-2014-0375).
This was registered at clinicalTrials.gov (NCT02185859) 7 July on 2014.
Patients
All adult patients undergoing elective breast cancer surgery at the University Hospital of Yon-
sei, a tertiary cancer center in Seoul, Republic of Korea, from July 2014 to July 2015 were
assessed for eligibility. Written informed consent was obtained from all participants who met
the following criteria: an American Society of Anesthesiologists (ASA) physical status of 1-2,
aged between 20 and 65 years, scheduled to undergo a mastectomy under general anesthesia
before enrollment. Only female patients were enrolled. Patients who had been experiencing
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pain due to any cause or who were taking analgesics were excluded from this clinical trial.
Additionally, patients with a body mass index (BMI) > 30 kg/m2, severe heart, kidney, or liver
disease, a psychiatric or neurological disorder, contraindications, or allergic responses to lido-
caine or magnesium were excluded from participation.
Interventions
On the morning of the day on which each patient was scheduled for mastectomy, using a ran-
dom number sequence created by an internet website (http://www.random.org), the patients
were randomly allocated to one of three groups in a 1:1:1 ratio: lidocaine group (group L,
N = 42), magnesium group (group M, N = 42), or control group (group C, N = 42). The assign-
ments were concealed in a sealed envelope, and randomization was not blocked or stratified.
The surgeons, patients, and those assessing outcomes were blinded to the group assignment. A
bolus dose of the studied drug was administered for 15 minutes immediately after the subject
was brought into the operating room and vital signs were checked from the beginning of anes-
thesia induction. Subsequently, a maintenance dose of the study drug was continuously
administered through the intravenous route, intraoperatively, and was later stopped just before
transferring the subject to a recovery room after surgery. Lidocaine (lidocaine hydrochloride)
and magnesium (magnesium sulfate) were administered at 2 mg/kg and 20 mg/kg, respectively,
for 15 minutes immediately after induction, followed by infusion at 2 mg/kg/h and 20 mg/kg/
h infusion, respectively. Patients in group C were administered and infused with the same vol-
ume of saline. The study drugs were prepared by a researcher who was not otherwise involved
in the study. Saline was added to the calculated drug doses to achieve a total volume of 50 ml,
and the treatments were labeled as “study drug” to ensure double-blinded administration. The
concentration of serum magnesium was checked immediately before drug infusion and 1 hour
after the infusion was stopped in all study groups. Additionally, we monitored patients closely
for any symptoms or signs of possible adverse events associated with lidocaine or magnesium
administration, such as electrocardiogram changes during anesthesia, prolonged neuromuscu-
lar paralysis, delayed awakening after anesthesia, complaint of a metallic taste, or abrupt
change in consciousness, including seizure-like movement postoperatively.
Clinical manifestations
Upon arrival in the operating room, routine monitoring, including electrocardiography, pulse
oximetry, and non-invasive blood pressure, were initiated. Anesthetic depth was monitored
using a bispectral index (BIS) monitor (Aspect A-20001, Aspect Medical system Inc., Newton,
MA). Patients were administered 0.2 mg glycopyrrolate intravenously, and anesthesia was
induced with a bolus administration of 1.5-2 mg/kg of propofol and 1-2 mg/kg of remifentanil;
anesthesia was maintained using 4-7% desflurane with an adjuvant infusion of 0.05–0.2 mg
kg/min of remifentanil. We adjusted the remifentanil dose to control the blood pressure range
to 20% of the baseline blood pressure in all patients. Rocuronium bromide, 0.6 mg/kg, was
injected to facilitate tracheal intubation in all patients. Mechanical ventilation was maintained
with a tidal volume of 8 ml/kg, and the ventilatory frequency was adjusted to maintain an end-
tidal carbon dioxide concentration of 35-40 mmHg with an air/oxygen mixture (fraction of
inspired oxygen 0.5). The body temperature was maintained at 36–37˚C. In all three groups,
the anesthetic depth was titrated to maintain a BIS scores between 40 and 60, and a mean arte-
rial pressure within 20% of the pre-induction values. At approximately 30 min before comple-
tion of the operation, 20 mg/kg propacetamol and 0.4 mg/kg nefopam were administered over
10 minutes, and 0.075 mg palonosetron was injected approximately 15 minutes before the end
of surgery. Propofol and remifentanil infusions were discontinued upon completion of the
Lidocaine vs. magnesium for mastectomy
PLOS ONE | DOI:10.1371/journal.pone.0173026 March 2, 2017 3 / 13
surgery, and patients were administered 25 μg/kg neostigmine with 50 μg/kg glycopyrrolate to
reverse any residual neuromuscular blockade. When consciousness and spontaneous respira-
tion were adequately restored, the endotracheal tube was removed and the patient recovered
for at least 30 minutes in the post-anesthesia recovery unit (PACU). Patients were transferred
to the ward and when they met the modified Aldrete scoring system discharge criteria
(score 9 with no score of 1 in any individual category) [11].
Assessments
Quality of recovery 40 survey. A researcher who was unaware of the patients’ group
assignments visited each patient to administer the Quality of Recovery 40 surveys (QoR-40) on
the day before surgery and on postoperative day (POD) 1, between 6:00 and 8:00 PM. The
QoR-40 is used to measure functional recovery and has been validated in patients undergoing
general surgical procedures [12]. The global QoR-40 score on POD 1 was the primary end-
point of this investigation. Five general quality-of-recovery dimensions are measured within
the QoR-40: physical comfort (12 items), emotional state (9 items), physical independence (5
items), psychological support (7 items), and pain (7 items). Each item is graded on a five-point
Likert scale, and the global scores range from 40 (extremely poor quality of recovery) to 200
(excellent quality of recovery). The QoR-40 scoring system was explained in detail to all sub-
jects, completed in the presence of a research assistant, and reviewed to ensure accurate com-
prehension of all questions.
Acute and chronic pain. A 0–10 point numeric rating scale (NRS) was used to measure
the degree of pain intensity during each patient’s stay in the PACU and ward. Higher scores
indicate a higher degree of pain. Symptoms that the patients complained of besides pain or post-
operative nausea and vomiting (PONV), as well as the administered drugs, were investigated,
and the length of the stay in the PACU was also recorded. Postoperative opioid consumption
(24 hours and 48 hours) was converted to the equivalent dose of intravenous morphine. We
assessed the patients’ postoperative chronic pain at 1 month and 3 months after surgery. We
checked whether the patients still suffered from the pain, and used the Korean version of short-
form McGill pain questionnaire (KSF-MPQ) [13] to measure sensory and affective pain in any
patients reporting pain. The KSF-MPQ consists of 17 items, 15 of which are adjectives from the
11 sensory (throbbing, shooting, stabbing, sharp, cramping, gnawing, hot-burning, aching,
heavy, tender and splitting) and 4 affective (tiring-exhausting, sickening, fearful and punishing-
cruel) categories that are rated on a 4-point intensity scale from 0 (not at all) to 3 (all the time).
Sensory categories focus on the nociceptive pain experience, and affective categories focus on
the emotional component of nociceptive pain [14]. The other two items assess overall pain
intensity: the present pain intensity and a verbal analogue scale score. These two items were
excluded in the present study as well as a previous study [13].
Statistical analyses
Ten-point difference represents a clinically relevant improvement in the quality of recovery
based on previously reported values of the mean and range of QoR-40 scores in patients after
anesthesia and surgery [15]. With that in mind, the estimated sample size was 37 patients per
group with a significance level of 5% (two-tailed), and a power of 90% was achieved when
there was a 10-point difference in the QoR-40 on POD 1 among the groups. Therefore, the
study sample size was set at 42 patients per group allowing for a dropout rate of up to 10%,
resulting in a total of 126 patients. Comparisons were made on an intention-to-treat basis,
since it was evident from the results that only the patients who actually received allocated inter-
ventions were analyzed.
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Continuous variables are expressed as the mean ± standard deviation (SD) (or median
[range]), and nominal factors are expressed as n (proportion, %). We performed a one-way
analysis of variance (ANOVA) for intergroup comparison of continuous variables. The hypoth-
esis of a normal distribution was confirmed using the Kolmogorov–Smirnov test. Nominal vari-
ables, such as the incidence of chronic postoperative surgical pain, are reported as numbers and
percentages; these variables were compared among groups by using the Chi-squared test and
Fisher’s exact test, as appropriate. Accordingly, the primary outcome (global QoR-40 scores)
was assessed using an ANOVA, and the secondary outcome (postoperative pain profiles) was
analyzed using ANOVA and chi-square tests. In cases of statistical significance, post hoc tests
were conducted with Bonferroni adjustment. For statistical analysis, we used SPSS (SPSS INC.,
Chicago, IL, USA) and considered P< 0.05 to be statistically significant.
Results
The CONSORT flowchart of present study is shown in Fig 1 Of the 127 patients, who were
assessed for eligibility and consented to participate to our study, one patient was excluded because
of not meeting inclusion criteria. No one declined to participate to this study. Finally, total 126
patients, who underwent breast cancer surgery (mastectomy) from July 2014 to July 2015, were
enrolled in this study. No one declined to this study. Among them, 10 patients (3 patients in
group L, 4 patients in group M, and 3 patients in group C) were lost during the follow-up period
because of a lack of patient co-operation. Therefore, we collected and analyzed the data from 116
patients (39 patients in group L, 38 patients in group M, and 39 patients in group C) within post-
operative 3 months. There were no significant differences among the groups regarding patient
Fig 1. CONSORT 2010 Flow Diagram.
doi:10.1371/journal.pone.0173026.g001
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characteristics (Table 1). No adverse or unintended effects were observed in the three groups.
Table 2 shows the perioperative parameters, where heart rate at extubation was significantly
lower in group L than in group C (P = 0.003), and the total amount of remifentanil consumption
was significantly lower in groups L and M than in group C (P< 0.001).
Primary endpoint
The global QoR-40 scores and the sub-scores of QoR-40 dimensions of the preoperative and
POD 1 are presented in Table 3. The preoperative scores of global QoR-40 and sub-scores of
QoR-40 dimensions were similar among the three groups. On POD 1, the global QoR-40 score
was significantly higher in group L than in group C (P = 0.003). In sub-scores of the QoR-40
dimensions, the emotional state and pain scores were significantly higher in group L than in
group C (P = 0.027 and P< 0.001, respectively).
Secondary endpoint
Outcomes associated with postoperative acute pain are presented in Table 4. At PACU and
postoperative 6-24 hours, the pain NRS was significantly lower in groups L and M than in
group C (P< 0.001 in both groups at PACU, and P = 0.001 and 0.046 at postoperative 6-24
hours, respectively). The pain NRS at postoperative 1-6 hours was significantly lower in group
L than in group C (P = 0.017). However, there were no significant differences in the postopera-
tive intravenous calculated morphine equivalent dose, incidence of PONV, antiemetic con-
sumption at the PACU and during POD 1, and in the length of the hospital stay (Table 4).
Table 5 shows postoperative chronic pain. At postoperative 3 months, SF-MPQ and SF-MPQ-
sensitive scores were significantly lower in group L than in group C (P = 0.046 and 0.036,
respectively).
Table 1. Patients’ characteristics.
Group L (n = 39) Group M (n = 38) Group C (n = 39) P - value
Demographic data
Age (year) 48.7 (6.4) 48.1 (7.5) 49.0 (6.9) 0.855
Height (cm) 157.6 (3.4) 157.6 (4.1) 157.1 (4.9) 0.840
Weight (kg) 56.4 (3.2) 55.7 (5.2) 55.0 (6.8) 0.530
ASA physical status 0.954
1 (number) 33 (84.6%) 31 (81.6%) 32 (82.1%)
2 (number) 6 (15.4%) 7 (18.4%) 7 (17.9%)
Surgical technique
Partial mastectomy 26 (66.7%) 22 (57.9%) 27 (69.2%)
Total mastectomy 13 (33.3%) 16 (42.1%) 12 (30.8%)
Lymph node dissection 0.502
Sentinel 5 (12.8%) 2 (5.3%) 7 (17.9%)
Axillary 10 (25.6%) 8 (21.1%) 12 (30.8%)
Sentinel plus Axillary 22 (56.4%) 25 (65.8%) 19 (48.7%)
Adjuvant chemotherapy 15 (38.5%) 14 (35.9%) 15 (39.5%) 0.971
Adjuvant radiotherapy 12 (30.8%) 10 (25.6%) 11 (28.9%) 0.903
Values are the mean (SD) or the number of patients (proportion, %), except in the case of age [median (IQR, minimum-maximum)]. SD; standard deviation
C, control; L, lidocaine; M, magnesium; ASA, American Society of Anesthesiologists
doi:10.1371/journal.pone.0173026.t001
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Discussion
The present study shows that intraoperative systemic lidocaine improves postoperative quality
of recovery, as measured by the QoR-40 survey. Additionally, lidocaine reduced the intensity
of chronic pain, and intraoperative opioids requirement in patients undergoing mastectomy
for breast cancer. However, intraoperative systemic magnesium was only effective in reducing
intraoperative opioid consumption and pain score in the early postoperative period. To our
knowledge, the present study is the first to report the effects of systemic lidocaine and magne-
sium on quality of recovery using the QoR-40 survey and chronic pain with SF-MPQ after
breast cancer surgery.
Adequate functional recovery soon after surgery is very important. Traditionally, several
parameters including pain, PONV, length of stay in the recovery room, and length of hospital
stay are used to estimate postoperative recovery status [16]. Recently, the QoR-40, which was
used to measure functional recovery in the immediate postoperative period in this study, has
emerged as the only quality of recovery measurement that fulfills the requirements for appro-
priateness, reliability, validity, responsiveness, precision, interpretability, acceptability, and
feasibility [17]. In the present study, when compared to saline infusion, intraoperative systemic
lidocaine infusion resulted in significantly higher global QoR-40 scores on POD 1. There was
also a significant enhancement in the sub-scores of the emotional state and pain QoR-40
Table 2. Perioperative parameters.
Group L (n = 39) Group M (n = 38) Group C (n = 39) P - value
Induction
HR (beats/min) 81.8 (12.2) 83.0 (13.9) 82.3 (12.4) 0.934
MAP (mmHg) 90.4 (11.2) 91.1 (12.4) 87.4 (11.5) 0.344
SPO2 (%) 98.5 (1.1) 98.4 (1.1) 98.9 (0.7) 0.104
Extubation
HR (beats/min)* 91.3 (10.4) 92.5 (11.6) 98.3 (10.9) 0.013
MAP (mmHg) 94.6 (7.2) 95.7 (12.2) 95.9 (8.7) 0.924
SPO2 (%) 100 100 100 1.000
Time (min) 5.8 (0.4) 5.9 (0.3) 6.0 (0.4) 0.208
Basal Mg (mg/dl)a 0.86 (0.05) 0.87 (0.07) 0.87 (0.07) 0.389
Postoperative Mg (mg/dl)a† 0.86 (0.05) 1.34 (0.05) 0.87 (0.07) < 0.001
Remifentanil (μg)§ 313.7 (116.4) 374.6 (138.0) 498.4 (150.2) < 0.001
Vasopressor (number) 15 (38.5%) 18 (47.4%) 21 (47.4%) 0.393
Magnesium (mg)k 0 (0) 3008.6 (301.3) 0 (0) < 0.001
Lidocaine (mg)¶ 321.8 (32.0) 0 (0) 0 (0) < 0.001
Surgical duration (min) 102.1 (24.4) 104.5 (34.2) 98.0 (24.2) 0.599
Anesthetic duration (min) 127.8 (26.6) 129.5 (35.4) 123.5 (22.5) 0.636
Administered fluid (ml) 750.3 (225.5) 792.1 (258.2) 801.4 (204.5) 0.582
Estimated blood loss (ml) 29.1 (31.0) 42.5 (68.0) 25.5 (32.7) 0.251
Values are mean (SD) or number of patients (proportion, %).
* Group L vs. Group C (P < 0.001), Group M vs. Group C (P = 0.061), Group L vs. Group M (P = 0.193)
† Group L vs. Group C (P = 0.967), Group M vs. Group C (P < 0.001), Group L vs. Group M (P < 0.001)
§ Group L vs. Group C (P < 0.001), Group M vs. Group C (P < 0.001), Group L vs. Group M (P = 0.154)
kGroup L vs. Group C (P = 1.000), Group M vs. Group C (P < 0.001), Group L vs. Group M (P < 0.001)
¶ Group L vs. Group C (P < 0.001), Group M vs. Group C (P = 1.000), Group L vs. Group M (P < 0.001)
C, control; L, lidocaine; M, magnesium; HR, heart rate; MAP, mean arterial pressure; SPO2, peripheral capillary oxygen saturation
a Mg was serum ionized magnesium concentration.
doi:10.1371/journal.pone.0173026.t002
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dimensions in patients in the lidocaine group when compared to patients in the control group.
Although a previous meta-analysis, which evaluated effects of systemic lidocaine on
Table 3. The global QoR-40 scores and sub-scores of QoR-40 dimensions among the three groups on the preoperative and postoperative day 1.
Group L (n = 39) Group M (n = 38) Group C (n = 39) P - value
QoR-40 Dimensions
Global QoR-40
Preoperative 176.9 (9.4) 175.9 (8.2) 176.4 (10.1) 0.904
Postoperative day 1* 179.3 (6.8) 176.6 (5.6) 173.9 (8.4) 0.005
Emotional state
Preoperative 35.1 (3.5) 34.0 (2.8) 35.0 (4.0) 0.296
Postoperative day 1† 38.8 (2.8) 37.1 (1.5) 37.1 (3.4) 0.010
Physical comfort
Preoperative 52.7 (3.6) 52.5 (4.1) 52.8 (4.2) 0.934
Postoperative day 1 55.3 (2.9) 55.4 (2.5) 54.4 (2.9) 0.234
Psychological support
Preoperative 30.8 (1.6) 31.2 (1.8) 30.7 (1.9) 0.347
Postoperative day 1 32.0 (1.5) 32.0 (1.1) 31.7 (1.0) 0.180
Physical independence
Preoperative 24.8 (0.5) 24.7 (0.5) 24.8 (1.3) 0.853
Postoperative day 1 22.3 (0.8) 22.4 (0.9) 22.1 (1.0) 0.452
Pain
Preoperative 33.8 (1.1) 33.7 (1.3) 33.4 (1.1) 0.346
Postoperative day 1§ 31.3 (1.7) 30.3 (1.6) 29.5 (2.0) < 0.001
Values are the mean (SD). SD; standard deviation
* Group L vs. Group C (P = 0.003), Group M vs. Group C (P = 0.233), Group L vs. Group M (P = 0.311)
† Group L vs. Group C (P = 0.027), Group M vs. Group C (P = 1.000), Group L vs. Group M (P = 0.023)
§ Group L vs. Group C (P < 0.001), Group M vs. Group C (P = 0.101), Group L vs. Group M (P = 0.050)
C, control; L, lidocaine; M, magnesium; QoR-40, quality of recovery 40
doi:10.1371/journal.pone.0173026.t003
Table 4. Postoperative acute pain data.
Group C (n = 39) Group L (n = 39) Group M (n = 38) P - value
In PACU
Pain NRS (0-10)* 2.8 (0.4) 2.2 (0.7) 2.2 (0.5) < 0.001
Analgesics requirement (number) 11 (28.2%) 10 (25.6%) 11 (28.9%) 0.966
IV ME consumption (mg) 1.7 (3.1) 1.3 (2.2) 1.7 (3.3) 0.758
Postoperative day 1
Pain NRS (0-10)
Postoperative 6-hour† 3.3 (0.9) 2.8 (0.8) 2.9 (0.8) 0.016
Postoperative 24-hour§ 2.9 (0.7) 2.4 (0.7) 2.5 (0.6) < 0.001
Analgesics requirement (number) 27 (69.2%) 27 (69.2%) 27 (71.1%) 1.000
IV ME consumption (mg) 5.3 (4.1) 4.6 (4.5) 4.6 (4.2) 0.754
Values are the mean (SD) or number of patients (proportion, %). SD; standard deviation
* Group L vs. Group C (P < 0.001), Group M vs. Group C (P < 0.001), Group L vs. Group M (P = 1.000)
† Group L vs. Group C (P = 0.017), Group M vs. Group C (P = 0.298), Group L vs. Group M (P = 0.758)
§ Group L vs. Group C (P = 0.001), Group M vs. Group C (P = 0.046), Group L vs. Group M (P = 0.601)
C, control; L, lidocaine; M, magnesium; PACU, post-anesthetic care unit; NRS, numeric rating scale; ME, morphine equivalent
doi:10.1371/journal.pone.0173026.t004
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postoperative recovery after abdominal surgery, concluded that intraoperative lidocaine infu-
sion improves patient rehabilitation and shortens hospital stays [18], there have been few studies
conducted on cases of breast cancer surgery. A recent study could not find any favorable effect
of intraoperative systemic lidocaine infusion on postoperative recovery, including measures of
pain and opioid consumption during the acute postoperative period after mastectomy [19].
However, that study used traditional parameters to measure postoperative quality of recovery
rather than the QoR-40. Further, we used 2 mg/kg of lidocaine as a loading dose for 15 minutes
immediately after the subject was brought into the operating room, while 1.5 mg/kg of lidocaine
was used in the previous study.
Our study showed that both lidocaine and magnesium reduced opioid consumption during
surgery and pain intensity during the acute postoperative period. One study, which compared
the effects of systemic lidocaine and magnesium on postoperative recovery with traditional
parameters for patients undergoing laparoscopic cholecystectomy, reported similar results as
ours [10]. However, there has been no study comparing the effects of systemic lidocaine and
magnesium in breast cancer surgery. Moreover, a few studies have focused on the effects of
systemic lidocaine or magnesium on postoperative pain in breast cancer surgery. For example,
a recent meta-analysis, which included only three studies for quantitative analysis, concluded
that intraoperative systemic lidocaine infusion had no effect on acute postoperative pain in
patients after breast cancer surgery [20]. Although our results showed that intraoperative sys-
temic magnesium had favorable effects on acute postoperative pain control, QoR-40 scores did
not improve. De Oliveira et al. showed that systemic magnesium enhanced QoR-40 scores at
the 24-hour postoperative period in patients undergoing outpatient segmental mastectomy
[21]. Considering that the mean postoperative magnesium serum concentration in that study
was 1.25 mg/dl and (compared to 1.36 mg/dl in the current study), further studies are needed
to investigate the correlation between magnesium serum concentration and its effects on post-
operative recovery.
Chronic or persistent postsurgical pain is defined as pain that develops after a surgical pro-
cedure that lasts at least 2 months, and where other causes (i.e., malignancy or chronic infec-
tion) have been excluded [22]. It has been reported that chronic pain could be associated with
Table 5. Postoperative chronic pain data.
Group L (n = 39) Group M (n = 38) Group C (n = 39) P - value
Postoperative 1 month
CPSP (number) 6 (15.4%) 7 (18.4%) 10 (25.6%) 0.542
SFMPQ (0-45) 9 (2.1) 9.8 (2.0) 10.6 (2.2) 0.296
SFMPQ-S (0-33) 6.7 (1.5) 7.3 (1.0) 7.8 (1.6) 0.327
SFMPQ-A (0-12) 2.3 (0.7) 2.4 (0.7) 2.7 (0.9) 0.582
Postoperative 3 months
CPSP (number) 7 (17.9%) 8 (21.1%) 14 (35.9%) 0.164
SFMPQ (0-45)* 8.9 (2.3) 10.6 (3.0) 12.7 (2.9) 0.017
SFMPQ-S (0-33)† 6.8 (1.7) 7.6 (1.9) 9.8 (2.5) 0.007
SFMPQ-A (0-12) 2.2 (0.7) 3.0 (1.1) 2.9 (0.6) 0.113
Values are the mean (SD) or number of patients (proportion, %). SD; standard deviation
* Group L vs. Group C (P = 0.046), Group M vs. Group C (P = 0.110), Group L vs. Group M (P = 1.000)
† Group L vs. Group C (P = 0.036), Group M vs. Group C (P = 0.069), Group L vs. Group M (P = 1.000)
CPSP, chronic postoperative surgical pain; SFMPQ, short-form McGill pain questionnaire; SFMPQ-S, short-form McGill pain questionnaire-sensitive;
SFMPQ-A, short-form McGill pain questionnaire-affective
doi:10.1371/journal.pone.0173026.t005
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postoperative acute pain and the use of analgesics [23], and may be connected with a patient’s
emotional aspects [24]. In our results revealed that systemic lidocaine improved not only post-
operative acute pain scores, but also emotional state and pain sub-scores of the QoR-40. More-
over, systemic lidocaine also decreased the intensity of chronic pain, which was evaluated
using the SF-MPQ at 3 months. The SF-MPQ is the most widely used tool for assessing the
quality and intensity of chronic pain [25], and is also a validated model for evaluating chronic
pain in Korea [13]. We used all 15 items (11 sensory and 4 affective items) to assess chronic
pain in our study. In terms of the effects of lidocaine on chronic pain, our results were similar
to those of a past study, which reported the effects of systemic lidocaine on persistent pain
after breast surgery [26]. In the present study, although systemic magnesium seemed to
decrease the intensity of chronic pain at 3 months compared to saline, there were no signifi-
cant differences between groups M and C. In a recent retrospective study [27], the periopera-
tive administration of magnesium also did not demonstrate a significant effect on the presence
of chronic pain after mastectomy, which is similar to that found in our prospective study.
Inhibition of N-methyl-D-aspartate (NMDA) receptors is a common analgesic mechanism
of lidocaine [28] and magnesium [29]. However, in our study, systemic liodocaine and magne-
sium showed different effects on postoperative recovery and chronic pain intensity. Even if we
consider that systemic magnesium decreased postoperative acute pain scores and ended to
enhance the global QoR-40 on POD 1 and KSF-MPQ at the 3-month postoperative period,
only systemic lidocaine had widely favorable effects on early postoperative recovery and
chronic pain control. The reason for this discrepancy might be that lidocaine acts via multiple
mechanisms for producing analgesia. For example, along with inhibiting NMDA receptors,
systemic lidocaine is known to block sodium channels in neurones [30], inhibits G protein-
coupled receptors [31], and mitigates neutrophil accumulation and the release of inflammatory
mediators [32].
Several limitations of this study should be addressed. First, we did not measure serum lido-
caine concentrations. If we had conducted this measurement, the effective dose of lidocaine
could have been determined, and the adverse effects of lidocaine could have been monitored
more specifically. Nonetheless, the safety of a low-dose lidocaine infusion has been demon-
strated in other studies [33,34]. Second, there is a possibility that a larger more bolus dose of
magnesium may have more favorable effects, although it remains uncertain whether this
would have resulted in a greater magnesium-mediated effect [9]. However, magnesium over-
dose could be very harmful to patients, and none of the patients who receiving magnesium in
the current study experienced adverse effects, such as [35] during magnesium infusion, or any
residual neuromuscular paralysis [35]. Third, we excluded the subjects who were suffered
from the pain or taking analgesics before surgery. We thought this population would introduce
an error in the subject sample in this prospective randomized clinical trial practically. For this
reason, we are unable to generalize the effect of lidocaine in all surgical patients having a
higher risk of developing chronic postoperative surgical pain, therefore, there is need to inves-
tigate all patients including with pain, or those who were taking analgesics before surgery in
larger further study. Third, we excluded subjects suffering from pain and/or taking analgesics
prior to surgery. We thought this population would introduce an error in the subject sample
in this prospective randomized clinical trial, practically. For this reason, we are unable to gen-
eralize the effects of lidocaine for all surgical patients including those that have a higher risk of
developing chronic postoperative surgical pain; therefore, there is a need to investigate all
patients including with those experiencing preoperative pain and those taking analgesics
before surgery in a larger further study.
In conclusion, intraoperative systemic lidocaine enhanced postoperative quality of recovery
after mastectomy, and improved chronic pain control. While the magnitude of improvement
Lidocaine vs. magnesium for mastectomy
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was statistically significant, it is probably less clinically relevant. Therefore, based on this study,
we suggest that intraoperative lidocaine administration could be a safe and useful method to
manage overall postoperative recovery for patients undergoing mastectomy due to breast
cancer.
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